Shareholder Votes

Sensei Biotherapeutics, Inc. shareholders approved Approval of the issuance of shares of the Company’s common stock upon conversion of the Company’s Series B Non-Voting Convertible Preferred Stock, which will (a) represent more than 20% of the shares of common stock outstanding and (b) result in the change of control of the Company pursuant to Nasda.

“The votes were cast as follows: Votes For Votes Against Abstained 747,293 3,397 14,832 Broker Non-Votes: 311,652 Proposal No. 3 was approved.”

Sensei Biotherapeutics, Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

“The votes were cast as follows: Votes For Votes Against Abstained 1,055,703 3,879 17,592 Proposal No. 2 was approved.”

Sensei Biotherapeutics, Inc. shareholders approved Election of two nominees to serve as directors until the 2029 annual meeting.

“The votes were cast as follows: Name Votes For Votes Withheld Bob Holmen 741,993 23,529 Kristian Humer 741,275 24,247 Broker Non-Votes: 311,652 All nominees were elected.”

ARGAN INC shareholders approved Election of nine directors at the 2026-06-10 meeting.

“At the 2026 Annual Meeting of the Stockholders of Argan, Inc. (“Argan” or the “Company”) held on June 10, 2026, the following three (3) matters were resolved by the stockholders of Argan. (1) The election of the following nine (9) members to the Board of Directors of the Company (the “Board”), each to serve until the 2027 Annual Meeting of Stockholders and until his/her successor has been elected and qualified or until his/her earlier resignation, death or removal: • Lisa L. Alexander • Cynthia A. Flanders • Peter W. Getsinger • William F. Griffin, Jr. • John R. Jeffrey, Jr. • William F. Leimkuhler • James W. Quinn • Karen A. Sweeney • David H. Watson”

CoreWeave, Inc. shareholders approved Advisory vote on the frequency of future advisory votes on named executive officer compensation at the 2026-06-08 meeting.

“Proposal 4 - Advisory Vote on the Frequency of Future Advisory Votes on the Compensation of the Company's Named Executive Officers The Company's stockholders voted to approve, on an advisory basis, holding future advisory votes on named executive officer compensation every year. The voting results were as follows: ONE YEAR TWO YEARS THREE YEARS ABSTENTIONS BROKER NON-VOTES 1,149,884,867 219,374 690,390 903,910 82,203,906”

CoreWeave, Inc. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-08 meeting.

“Proposal 3 - Advisory Vote on the Compensation of the Company's Named Executive Officers The Company’s stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers. The voting results were as follows: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 1,146,482,539 2,756,059 2,459,943 82,203,906”

CoreWeave, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-06-08 meeting.

“Proposal 2 - Ratification of Appointment of Independent Registered Public Accounting Firm The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The voting results were as follows: FOR AGAINST ABSTENTIONS BROKER NON-VOTES 1,230,533,541 1,433,238 1,935,668 0”

CoreWeave, Inc. shareholders approved Election of one Class I director at the 2026-06-08 meeting.

“Proposal 1 - Election of Director The Company’s stockholders approved the election of one Class I director to hold office until the 2029 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation, disqualification, retirement, or removal. The voting results were as follows: NOMINEE FOR WITHHELD BROKER NON-VOTES Michael Intrator 1,073,688,776 78,009,765 82,203,906”

Taboola.com Ltd. shareholders approved Approval and re-appointment of Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as the Company's independent registered public accounting firm for the year ending December 31, 2026 and until the next annual general meeting of shareholders at the 2026-06-09 meeting.

“Proposal 5: Approval and re-appointment of Kost, Forer, Gabbay & Kasierer, a member of Ernst & Young Global, as the Company's independent registered public accounting firm for the year ending December 31, 2026 and until the next annual general meeting of shareholders For Against Abstain Broker Non-Votes 168,627,937 626,505 757,550 -”

Taboola.com Ltd. shareholders approved Approval of the compensation terms for our Chief Executive Officer (and Director) at the 2026-06-09 meeting.

“Proposal 4: Approval of the compensation terms for our Chief Executive Officer (and Director) For Against Abstain Broker Non-Votes 110,976,304 11,922,890 439,478 46,673,320”

Taboola.com Ltd. shareholders approved Approval of Compensation Policy for Executives and Directors at the 2026-06-09 meeting.

“Proposal 3: Approval of Compensation Policy for Executives and Directors* For Against Abstain Broker Non-Votes 94,075,407 6,019,060 23,244,205 46,673,320”

Taboola.com Ltd. shareholders approved Advisory proposal on executive compensation at the 2026-06-09 meeting.

“Proposal 2: Advisory proposal on executive compensation For Against Abstain Broker Non-Votes 116,848,846 5,965,232 524,594 46,673,320”

Taboola.com Ltd. shareholders approved Re-election of two Class II directors at the 2026-06-09 meeting.

“Proposal 1: Re-election of two Class II directors For Against Abstain Broker Non-Votes Nechemia J. Peres 95,074,350 27,496,480 767,842 46,673,320 Gilad Shany 96,453,223 25,578,895 1,306,554 46,673,320”

Quanterix Corp shareholders rejected Approve an amendment and restatement of the Company's 2017 Employee, Director and Consultant Equity Incentive Plan to implement certain equity compensation best practices and extend the term of the 2017 Plan through June 9, 2031 at the 2026-06-09 meeting.

“Proposal 4 — Approval of an Amendment and Restatement of the 2017 Plan: For Against Abstain Broker Non-Votes 9,677,232 24,004,124 15,723 5,180,238”

Quanterix Corp shareholders approved Ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“Proposal 3 — Ratification of KPMG, LLP as the Company’s Independent Registered Public Accounting Firm: For Against Abstain Broker Non-Votes 38,728,204 137,595 11,518 0”

Quanterix Corp shareholders approved Advisory vote to approve the compensation of the Company's named executive officers at the 2026-06-09 meeting.

“Proposal 2 — Advisory Vote to Approve the Compensation of the Company’s Named Executive Officers: For Against Abstain Broker Non-Votes 27,679,636 3,881,516 2,135,927 5,180,238”

Quanterix Corp shareholders approved Election of directors at the 2026-06-09 meeting.

“Proposal 1 — Election of Directors: For Withheld Abstain Broker Non-Votes William P. Donnelly 30,927,792 2,757,653 11,634 5,180,238 Ivana Magovčević-Liebisch, Ph.D., J.D. 30,314,520 3,375,724 6,835 5,180,238”

Wheels Up Experience Inc. shareholders approved Approval of LTIP Amendment to increase shares available under A&R 2021 LTIP and extend termination date to March 31, 2036 at the 2026-06-09 meeting.

“The Stockholders voted to approve the LTIP Amendment to increase the aggregate number of shares of Common Stock of the Company available for awards made under the A&R 2021 LTIP and extend the termination date of such plan to March 31, 2036: Votes For Votes Against Abstentions Broker Non-Votes 504,934,147 2,788,304 81,473 39,845,045”

Wheels Up Experience Inc. shareholders approved Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“The Stockholders voted to ratify, on a non-binding, advisory basis, the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026: Votes For Votes Against Abstentions 544,018,799 3,043,148 587,022”

Wheels Up Experience Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation for fiscal year ended December 31, 2025 at the 2026-06-09 meeting.

“The Stockholders voted to approve the non-binding, advisory vote to approve named executive officer compensation for the fiscal year ended December 31, 2025: Votes For Votes Against Abstentions Broker Non-Votes 504,699,609 2,937,327 166,988 39,845,045”

Wheels Up Experience Inc. shareholders approved Election of four Class II directors at the 2026-06-09 meeting.

“The Stockholders voted to elect four Class II directors on the Board to serve until the 2029 annual meeting of stockholders or until the election and qualification of their respective successors: Nominee Votes For Withheld Broker Non-Votes Andrew Davis 506,447,451 1,356,473 39,845,045 Roger Farah 507,002,005 801,919 39,845,045 George Mattson 506,965,589 838,335 39,845,045 Gregory Summe 507,108,505 695,419 39,835,045”

Ramaco Resources, Inc. shareholders approved Approve, on an advisory basis, the compensation paid by the Company to its named executive officers at the 2026-06-10 meeting.

“Shareholders were asked to vote to approve, on an advisory basis, the compensation paid by the Company to its named executive officers. The final vote totals are below. Votes For Votes Against Abstentions Broker Non-Votes 35,914,373 2,997,223 159,750 12,319,208”

Ramaco Resources, Inc. shareholders approved Approve an amendment to the Company’s Long-Term Incentive Program (the “LTIP”) to increase the number of shares of Class A common stock subject to the LTIP by an additional 4,000,000 shares at the 2026-06-10 meeting.

“Shareholders were asked to vote to approve an amendment to the Company’s Long-Term Incentive Program (the “LTIP”) to increase the number of shares of Class A common stock subject to the LTIP by an additional 4,000,000 shares. Votes For Votes Against Abstentions Broker Non-Votes 33,603,634 5,379,416 88,296 12,319,208”

Ramaco Resources, Inc. shareholders approved Ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-10 meeting.

“Shareholders were asked to vote to ratify the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. There were no broker non-votes. The final vote totals are below. Votes For Votes Against Abstentions 51,176,895 123,273 90,386”

Ramaco Resources, Inc. shareholders approved Election of Directors at the 2026-06-10 meeting.

“Shareholders were asked to vote upon the election of directors. The final vote totals are below. Name Votes For Votes Withheld Broker Non-Votes Bryan H. Lawrence 34,240,156 4,831,190 12,319,208 David E.K. Frischkorn, Jr. 33,142,435 5,928,911 12,319,208 Michael R. Graney 38,844,304 227,042 12,319,208”

Astrana Health, Inc. shareholders approved Approval of the 2024 Plan. at the 2026-06-10 meeting.

“Proposal 4. Approval of the 2024 Plan For Against Abstain Broker Non-Votes 34,679,879 701,303 35,295 8,356,118”

Astrana Health, Inc. shareholders approved Advisory vote on the compensation program for the Company's named executive officers as disclosed in the Proxy Statement. at the 2026-06-10 meeting.

“3. The compensation program for the Company’s named executive officers as disclosed in Proxy Statement was approved, on an advisory, non-binding basis.”

Astrana Health, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-10 meeting.

“2. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”

Astrana Health, Inc. shareholders approved Election of nine directors to the Board, each to hold office until the 2027 Annual Meeting of Stockholders. at the 2026-06-10 meeting.

“The voting results for each such matter were as follows: Proposal 1. Election of Directors Nominee For Withheld Broker Non-Votes Kenneth Sim, M.D. 33,456,519 1,959,958 8,356,118 Thomas S. Lam, M.D., M.P.H. 33,486,509 1,929,968 8,356,118 John Chiang 34,104,046 1,312,431 8,356,118 Weili Dai 33,926,696 1,489,781 8,356,118 Linda Dong 33,330,641 2,085,836 8,356,118 J. Lorraine Estradas, R.N., B.S.N. M.P.H. 32,171,774 3,244,703 8,356,118 Mitchell W. Kitayama 33,320,506 2,095,971 8,356,118 Matthew Mazdyasni 33,610,789 1,805,688 8,356,118 David G. Schmidt 33,198,453 2,218,024 8,356,118”

Exzeo Group, Inc. shareholders approved Ratification of the appointment of Forvis Mazars, LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-09 meeting.

“Ratification of the appointment of Forvis Mazars, LLP, as Exzeo's independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Exzeo Group, Inc. shareholders approved Election of two Class A directors at the 2026-06-09 meeting.

“Paresh Patel and Irene Hurst were elected to the board of directors at the meeting.”

Maze Therapeutics, Inc. shareholders approved To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-08 meeting.

“Proposal 2: Ratification of Appointment of Independent Registered Public Accounting Firm. Votes For Votes Against Abstentions Broker Non-Votes 44,557,778 728 101,523 0”

Maze Therapeutics, Inc. shareholders approved To elect each of Jason Coloma, Ph.D. and Neil Kumar, Ph.D. as a Class I director to serve until the Company's 2029 annual meeting of stockholders at the 2026-06-08 meeting.

“Proposal 1: Election of Directors. Nominee Votes For Votes Withheld Broker Non-Votes Jason Coloma, Ph.D. 35,792,536 5,926,467 2,941,026 Neil Kumar, Ph.D. 34,056,425 7,662,578 2,941,026”

MARKETAXESS HOLDINGS INC shareholders rejected A stockholder proposal regarding changes to the existing special stockholder meeting right. at the 2026-06-10 meeting.

“Proposal 4 — A stockholder proposal regarding changes to the existing special stockholder meeting right. The results were as follows: For Against Abstain Broker Non-Votes 8,729,100 21,935,501 31,602 1,230,593”

MARKETAXESS HOLDINGS INC shareholders approved Advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement pursuant to the SEC’s compensation disclosure rules (referred to as the "say-on-pay" proposal). at the 2026-06-10 meeting.

“Proposal 3 — Advisory vote on the compensation of the Company’s named executive officers as disclosed in the proxy statement pursuant to the SEC’s compensation disclosure rules (referred to as the “say-on-pay” proposal). The results were as follows: For Against Abstain Broker Non-Votes 30,009,045 677,528 9,630 1,230,593”

MARKETAXESS HOLDINGS INC shareholders approved Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-10 meeting.

“Proposal 2 — Ratification of the selection of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results were as follows: For Against Abstain 30,900,982 1,018,139 7,675”

MARKETAXESS HOLDINGS INC shareholders approved Election of Directors at the 2026-06-10 meeting.

“Item 5.07 Submission of Matters to a Vote of Security Holders. On June 10, 2026, MarketAxess Holdings Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”). A total of 31,926,796 shares of common stock were present or represented by proxy at the 2026 Annual Meeting, representing 90.75% of the issued and outstanding shares entitled to vote at the meeting. The proposals voted upon and the final results of the vote were as follows: Proposal 1 — Election of Directors. The results were as follows: Director For Against Abstain Broker Non-Votes Carlos M. Hernandez 30,479,824 207,405 8,974 1,230,593 Christopher R. Concannon 30,479,238 204,344 12,621 1,230,593 Nancy Altobello 30,083,289 603,382 9,532 1,230,593 Steven L. Begleiter 30,576,039 114,228 5,936 1,230,593 Jane Chwick 30,223,297 463,327 9,579 1,230,593 Douglas Cifu 30,656,324 34,006 5,873 1,230,593 William F. Cruger 29,259,117 1,431,155 5,931 1,230,593 Kourtney Gibson 30,417,533 272,942 5,728 1,23”

APARTMENT INVESTMENT & MANAGEMENT CO shareholders approved Advisory vote to approve the compensation of executive officers disclosed in Aimco’s proxy statement at the 2026-06-10 meeting.

“Advisory vote to approve the compensation of executive officers disclosed in Aimco’s proxy statement. Aimco’s stockholders gave advisory approval of the executive compensation program, and the voting results are set forth below: For Against Abstentions Broker Non-Votes 105,737,910 1,060,791 388,595 15,408,377”

APARTMENT INVESTMENT & MANAGEMENT CO shareholders approved The selection of Grant Thornton LLP as Aimco’s independent registered accounting firm for the 2026 fiscal year at the 2026-06-10 meeting.

“The selection of Grant Thornton LLP as Aimco’s independent registered accounting firm for the 2026 fiscal year was ratified as follows: For Against Abstentions Broker Non-Votes 122,448,341 44,640 102,692 —”

APARTMENT INVESTMENT & MANAGEMENT CO shareholders approved Election of nine directors, for a term of one year each, to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified. at the 2026-06-10 meeting.

“Aimco’s stockholders elected each of the nine nominees for director, and the voting results are set forth below: For Against Abstentions Broker Non-Votes Wes Powell 107,005,634 106,237 21,425 15,408,377”

Syndax Pharmaceuticals Inc shareholders approved Approval of the 2026 ESPP at the 2026-06-10 meeting.

“For Against Abstain Broker Non-Votes 58,661,941 74,047 26,875 8,034,588”

Syndax Pharmaceuticals Inc shareholders approved Approval of the 2026 Plan at the 2026-06-10 meeting.

“For Against Abstain Broker Non-Votes 33,333,263 25,392,051 37,549 8,034,588”

Syndax Pharmaceuticals Inc shareholders approved Ratification of selection of independent registered public accounting firm at the 2026-06-10 meeting.

“For Against Abstain Broker Non-Votes 66,603,912 162,947 30,592 —”

Syndax Pharmaceuticals Inc shareholders approved Advisory vote on executive compensation at the 2026-06-10 meeting.

“For Against Abstain Broker Non-Votes 55,688,039 2,985,350 89,474 8,034,588”

Syndax Pharmaceuticals Inc shareholders approved Election of directors at the 2026-06-10 meeting.

“Pierre Legault 37,294,888 21,467,975 8,034,588 Michael A. Metzger 58,113,110 649,753 8,034,588”

Clean Energy Fuels Corp. shareholders approved Advisory, non-binding approval of the compensation of the Company’s named executive officers at the 2026-06-10 meeting.

“The holders of the Company’s common stock approved, on an advisory, non-binding basis, the compensation of the Company’s named executive officers.”

Clean Energy Fuels Corp. shareholders approved Ratification of appointment of KPMG LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-10 meeting.

“The holders of the Company’s common stock ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”

Clean Energy Fuels Corp. shareholders approved Election of six directors for a one-year term at the 2026-06-10 meeting.

“The holders of the Company’s common stock elected to the Board the six director nominees set forth in the proxy statement for the Annual Meeting, each to serve for a one-year term until the Company’s next annual meeting of stockholders and until his or her respective successor is duly elected and qualified or until his or her earlier resignation or removal.”

Amplitude, Inc. shareholders approved Advisory (Non-Binding) Approval of the Compensation of the Company’s Named Executive Officers at the 2026-06-09 meeting.

“The Company’s stockholders approved, on an advisory (non-binding) basis, the compensation of the Company’s named executive officers.”

Amplitude, Inc. shareholders approved Ratification of Appointment of Independent Registered Public Accounting Firm at the 2026-06-09 meeting.

“The Company’s stockholders ratified the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”